A detailed history of Brevan Howard Capital Management LP transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 13,868 shares of AVIR stock, worth $44,654. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,868
Holding current value
$44,654
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.17 - $4.02 $43,961 - $55,749
13,868 New
13,868 $46,000
Q1 2024

May 15, 2024

SELL
$3.09 - $4.56 $15,165 - $22,380
-4,908 Reduced 19.08%
20,809 $84,000
Q4 2023

Feb 14, 2024

BUY
$2.8 - $3.35 $72,007 - $86,151
25,717 New
25,717 $78,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $268M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Brevan Howard Capital Management LP Portfolio

Follow Brevan Howard Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brevan Howard Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Brevan Howard Capital Management LP with notifications on news.